Food Allergies
- FARE (Food Allergy Research & Education) Resources
- Common Allergens
- Understanding Food Labels
- It’s a Disease, Not a Diet: A documentary about life with food allergies
- Recognize and Respond to Anaphylaxis
- Children With Food Allergies
- Living with Food Allergies: Preparing for College
- Omalizumab for the Treatment of Multiple Food Allergies
- Omalizumab Prescribing Information
- Peanut Oral Immunotherapy Prescribing Information
- Clinical Burden of Food Allergies: Insights from the FARE Patient Registry
- Mental Health Burden of Food Allergies: Insights from Patients and Their Caregivers from FARE Patient Registry
- Food Allergies: National Institute of Allergy and Infectious Diseases
- Food Allergy Information from the American College of Allergy, Asthma & Immunology
- Kids With Food Allergies
- FARE powered by Sifter Shopping Tool for Food Allergy Needs
- Food allergy, mechanisms, diagnosis and treatment: Innovation through a multi-targeted approach
- FDA: Food Allergies
- What you need to know about the new guidelines for the diagnosis and management of food allergy in the U.S.
- Managing food allergy: GA2LEN guideline 2022
- Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary for Patients, Families, and Caregivers
- AR101 Oral Immunotherapy for Peanut Allergy
Asthma
- Dupilumab Prescribing Information
- Tezepelumab Prescribing Information
- Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
- Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma
- Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
- 2022 GINA Pocket Guide for Asthma Management and Prevention (for Adults and Children Older Than 5 Years)
- 2022 GINA Main Report: Global Strategy for Asthma Management and Prevention
- American Lung Association: Severe Asthma
- Biological treatments for severe asthma: A major advance in asthma care
- Advances and recent developments in asthma in 2020
- Asthma biologics: Comparing trial designs, patient cohorts and study results
- Anti-IL5 therapies for asthma
- Mepolizumab Prescribing Information
- Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study
- Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype
- Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A Post Hoc Analysis
- Usability of mepolizumab single-use prefilled syringe for patient self-administration
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
- National Jewish Health Inhaler Instructional Videos
Chronic Spontaneous Urticaria (CSU)
- Current and Emerging Therapies for Chronic Spontaneous Urticaria: A Narrative Review
- Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances
- Dupilumab Improves Urticaria Activity And Quality Of Life In Patients With Chronic Spontaneous Urticaria (CSU)
- Dupilumab Significantly Reduces Itch and Hives in Patients With Chronic Spontaneous Urticaria: Results From a Phase 3 Trial (LIBERTY-CSU CUPID Study A)
- Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks
- Urticaria
- Omalizumab Re-Treatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial
- Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study
- Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria
- Ligelizumab for Chronic Spontaneous Urticaria
- Dupilumab Efficacy In Patients With Chronic Spontaneous Urticaria By Ige Level: Liberty-CSU Cupid Study A
- Novel biologics for treatment of chronic spontaneous urticaria
- Dupilumab: A Review of Present Indications and Off-Label Uses
- Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial
- Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial
- Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) UrticariaA Meta-analysis of “Real-world” Evidence
- Total IgE as a Marker for Chronic Spontaneous Urticaria
- Chronic Idiopathic Urticaria
- Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances
- The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
- XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria
- The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU
- A Comparison of the United States and International Perspective on Chronic Urticaria Guidelines
- Patient education: Hives (urticaria) (Beyond the Basics)
- Joint Task Force Guidelines: The diagnosis and management of acute and chronic urticaria: 2014 update
- Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
- Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study
- Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study